BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
The India pharma market grew a robust 51.5% in April.
A rebound in volume growth and renewed demand for Covid-19 drugs amid the second wave were primary drivers of this growth.
Acute therapy sales, overall, grew a strong 75.2% while chronic and sub-chronic therapies grew 24.2% and 53.0%, respectively.
The Covid-19 outbreak had a significant effect on industry volumes.
In April, the effect was behind and, on a lower base, industry volumes grew 34.5%.
A blended price hike in April was of 7% and launches contributed 10 percentage points of the growth.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.